AptarGroup

Last updated
AptarGroup, Inc.
Aptar
Company type Public
IndustryPackaging and drug delivery devices
Founded1992;32 years ago (1992) [1]
Headquarters
Crystal Lake, Illinois
,
U.S.
Key people
Stephan Tanda (CEO), Robert Kuhn (CFO), Shiela Vinczeller (CHRO)
Products
  • Spray pumps and valves
  • Metered-dose inhaler valves
  • Nasal spray systems
  • Dispensing closures
  • Elastomer components for injection devices
  • Active packaging
RevenueIncrease2.svg US$3.2 billion (2022)
Decrease2.svg $339 million [2]  (2020)
Decrease2.svg $214 million [3]  (2020)
Total assets Increase2.svg $3.990 million [4]  (2020)
Total equity Increase2.svg US$1.851 billion [5]  (2020)
Number of employees
13,000 (2020) [6]
Subsidiaries
  • Next Breath
  • Cohero Health
  • Gateway Analytical
  • SeaquistPerfect Dispensing
  • Seaquist Closures
  • CSP Technologies
  • Noble International
  • FusionPKG
  • Voluntis
  • WeiHai Hengyu Medical Products Co., Ltd.
  • Nanopharm
Website https://www.aptar.com/

AptarGroup, Inc., also known as Aptar, is a United States-based global manufacturer of consumer dispensing packaging and drug delivery devices. [7] [1] The group has manufacturing operations in 18 countries. [8]

Contents

History

The company began as Werner Die & Stamping in Cary, Illinois, in 1946 and later incorporated as AptarGroup in 1992. [1] [9] Aptar originally developed spray valves and pumps for consumer and household products. The company later began producing nasal administration and pulmonary drug delivery devices such as nasal spray systems and metered-dose inhaler valves. [9] [10] [11] [12] Biotech and pharmaceutical companies use Aptar's different Unidose and Bidose devices for the single or two-shot intranasal delivery of different medicines. [13]

In 2016, Aptar announced that it provided the delivery system for Adapt Pharma's Narcan. [14] Narcan is a naloxone hydrochloride nasal spray used as an emergency treatment for opioid overdoses. [14] Aptar's liquid spray drug delivery technology platform works as a ready-to-use, single-shot, unit-dose system for Narcan. It was the first FDA approved nasally administered, ready-to-use medication used to reverse the effects of an opioid overdose. [14] Narcan does not require any assembly, medical training, or needle injection. [15]

In 2016, Aptar entered into an agreement with Becton Dickinson & Company to develop new self-injection devices. [16] [17]

Aptar entered into an agreement in 2016 with Propeller Health Partners to develop a digitally connected medication inhaler. [18] The company made an investment in Propeller Health Partners (now part of Resmed) in 2018. [19]

In July 2019, the FDA-approved Aptar Pharma's Unidose Powder System as the first intranasally-delivered, needle-free rescue treatment for severe hypoglycemia. [13]

In 2020, during the COVID-19 pandemic, Aptar invested in new tools to accelerate its molding equipment and assembly machines for pumps, but it still wasn't enough to keep up with demand. [20]

Acquisitions

In 2012, Aptar acquired Stelmi, a manufacturer of elastomer primary packaging components. [21] In 2016, Aptar acquired Mega Airless, a manufacturer of airless packaging solutions. [22] In 2018, Aptar acquired CSP Technologies, a material science company that manufactures active packaging solutions. [23]

In June 2019, Aptar acquired two companies, Nanopharm and Gateway Analytical. [24] In November 2019, the company acquired Noble International, which specializes in training devices and patient onboarding. [25] In February 2020, Aptar acquired FusionPKG, a makeup packaging company. [26] [27]

In November 2020, the company acquired the digital respiratory health company Cohero Health. [28] [29]

In July 2021 Aptar acquired the digital therapeutics company, Voluntis (ENXTPA: ALVTX), and 80% of the equity interests of Weihai Hengyu Medical Products Co., Ltd., a Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery. [30]

Sustainability

Aptar was named to Barron's list of the Top 100 Most Sustainable U.S. Companies in 2019, 2020, 2021, and 2022. [31] [32] [33] [34] At the end of 2020, 85% of the company’s global electricity use came from renewable sources. [35] It was also named by Newsweek as one of America's Most Responsible Companies in 2021, [36] 2022, [37] and 2023 [38] and received an A score for climate change from the Climate Disclosure Project. [39]

In September 2019, the company announced a partnership with Loop, a shopping platform from TerraCycle that delivers products in reusable containers. [40] The company made the Forbes Green Growth 50 List in 2021. [41]

Related Research Articles

<span class="mw-page-title-main">Naloxone</span> Opioid receptor antagonist

Naloxone is an opioid antagonist: a medication used to reverse or reduce the effects of opioids. For example, it is used to restore breathing after an opioid overdose. Effects begin within two minutes when given intravenously, five minutes when injected into a muscle, and ten minutes as a nasal spray. Naloxone blocks the effects of opioids for 30 to 90 minutes.

<span class="mw-page-title-main">Route of administration</span> Path by which a drug, fluid, poison, or other substance is taken into the body

In pharmacology and toxicology, a route of administration is the way by which a drug, fluid, poison, or other substance is taken into the body.

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Purdue Pharma</span> American pharmaceutical company (1892–2019 bankruptcy)

Purdue Pharma L.P., formerly the Purdue Frederick Company (1892–2019), was an American privately held pharmaceutical company founded by John Purdue Gray. It was sold to Arthur, Mortimer, and Raymond Sackler in 1952, and then owned principally by the Sackler family and their descendants.

<span class="mw-page-title-main">Nalmefene</span> Opioid antagonist

Nalmefene is a medication that is used in the treatment of opioid overdose and alcohol dependence. Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.

<span class="mw-page-title-main">Minneapolis Fire Department</span> Fire department in Minneapolis

The Minneapolis Fire Department provides fire protection and first responder emergency medical services to the city of Minneapolis, Minnesota.

<span class="mw-page-title-main">Substance abuse prevention</span> Measures to prevent the consumption of licit and illicit drugs

Substance abuse prevention, also known as drug abuse prevention, is a process that attempts to prevent the onset of substance use or limit the development of problems associated with using psychoactive substances. Prevention efforts may focus on the individual or their surroundings. A concept that is known as "environmental prevention" focuses on changing community conditions or policies so that the availability of substances is reduced as well as the demand. Individual Substance Abuse Prevention, also known as drug abuse prevention involves numerous different sessions depending on the individual to help cease or reduce the use of substances. The time period to help a specific individual can vary based upon many aspects of an individual. The type of Prevention efforts should be based upon the individual's necessities which can also vary. Substance use prevention efforts typically focus on minors and young adults – especially between 12–35 years of age. Substances typically targeted by preventive efforts include alcohol, tobacco, marijuana, inhalants, coke, methamphetamine, steroids, club drugs, and opioids. Community advocacy against substance use is imperative due to the significant increase in opioid overdoses in the United States alone. It has been estimated that about one hundred and thirty individuals continue to lose their lives daily due to opioid overdoses alone.

<span class="mw-page-title-main">Opioid overdose</span> Toxicity due to excessive consumption of opioids

An opioid overdose is toxicity due to excessive consumption of opioids, such as morphine, codeine, heroin, fentanyl, tramadol, and methadone. This preventable pathology can be fatal if it leads to respiratory depression, a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils, and unconsciousness; however, its onset can depend on the method of ingestion, the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids, individuals who survived also faced adverse complications, including permanent brain damage.

Medidata Solutions is an American technology company that develops and markets software as a service (SaaS) for clinical trials. These include protocol development, clinical site collaboration and management; randomization and trial supply management; capturing patient data through web forms, mobile health (mHealth) devices, laboratory reports, and imaging systems; quality monitor management; safety event capture; and monitoring and business analytics. Headquartered in New York City, Medidata has locations in China, Japan, Singapore, South Korea, the United Kingdom, and the United States.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

<span class="mw-page-title-main">Opioid epidemic in the United States</span> Ongoing overuse of opioid medication in the US

There is an ongoing opioid epidemic in the United States, originating out of both medical prescriptions and illegal sources. The epidemic began in the United States in the late 1990s, according to the Centers for Disease Control and Prevention (CDC), when opioids were increasingly prescribed for pain management, resulting in a rise in overall opioid use throughout subsequent years.

Phil Skolnick is an American neuroscientist and pharmacologist most widely known for his work on the psychopharmacology of depression and anxiety, as well as on addiction medicine. Author of more than 500 published papers, Skolnick's most notable accomplishments include elucidating the role of the NMDA system in depression therapeutics, demonstrating the existence of endogenous benzodiazepine receptor ligands, and spearheading the National Institute on Drug Abuse's partnership to develop a naloxone atomizer for reversal of acute opioid overdose. Skolnick's work also laid the foundation for the development of ketamine as a rapid-acting antidepressant.

<span class="mw-page-title-main">Opioid epidemic</span> Deaths due to abuse of opioid drugs

The opioid epidemic, also referred to as the opioid crisis, is the rapid increase in the overuse, misuse/abuse, and overdose deaths attributed either in part or in whole to the class of drugs called opiates/opioids since the 1990s. It includes the significant medical, social, psychological, demographic and economic consequences of the medical, non-medical, and recreational abuse of these medications.

<span class="mw-page-title-main">Sean Scanlon (politician)</span> American politician

Sean Scanlon is an American politician who is the current Comptroller of Connecticut. Scanlon previously served in the Connecticut House of Representatives from the 98th district.

<span class="mw-page-title-main">Scott Hadland</span> American physician and scientist

Scott E. Hadland is a Canadian-American physician and scientist who serves as a pediatrician, and addiction specialist at Massachusetts General Hospital and Harvard Medical School, where he is the Chief of the Division of Adolescent and Young Adult Medicine. He previously served as an addiction specialist at the Grayken Center for Addiction at Boston Medical Center.

Harm reduction consists of a series of strategies aimed at reducing the negative impacts of drug use on users. It has been described as an alternative to the U.S.'s moral model and disease model of drug use and addiction. While the moral model treats drug use as a morally wrong action and the disease model treats it as a biological or genetic disease needing medical intervention, harm reduction takes a public health approach with a basis in pragmatism. Harm reduction provides an alternative to complete abstinence as a method for preventing and mitigating the negative consequences of drug use and addiction.

In response to the surging opioid prescription rates by health care providers that contributed to the opioid epidemic in the United States, US states began passing legislation to stifle high-risk prescribing practices. These new laws fell primarily into one of the following four categories:

  1. Prescription Drug Monitoring Program (PDMP) enrollment laws: prescribers must enroll in their state's PDMP, an electronic database containing a record of all patients' controlled substance prescriptions
  2. PDMP query laws: prescribers must check the PDMP before prescribing an opioid
  3. Opioid prescribing cap laws: opioid prescriptions cannot exceed designated doses or durations
  4. Pill mill laws: pain clinics are closely regulated and monitored to minimize the prescription of opioids non-medically

References

  1. 1 2 3 "AptarGroup Inc". Bloomberg. Retrieved 2019-08-12.
  2. ↑ "AptarGroup Operating Income 2006-2021 | ATR".
  3. ↑ "AptarGroup Net Income 2006-2021 | ATR".
  4. ↑ "AptarGroup Total Assets 2006-2021 | ATR".
  5. ↑ "AptarGroup Share Holder Equity 2006-2021 | ATR".
  6. ↑ "AptarGroup: Number of Employees 2006-2021 | ATR".
  7. ↑ "AptarGroup Inc". SEC. Retrieved 2019-08-12.
  8. ↑ "Aptar Joins the World Business Council for Sustainable Development". World Business Council for Sustainable Development (WBCSD). 2019-02-05. Retrieved 2019-08-12.
  9. 1 2 "History of AptarGroup, Inc. – FundingUniverse". Funding Universe. Retrieved 2019-08-12.
  10. ↑ Mallory, Mike (2017-10-25). "Crystal Lake-based Aptar Pharma's opioid overdose reversal device goes nationwide". Northwest Herald. Archived from the original on 2017-10-26.
  11. ↑ Strang, John; McDonald, Rebecca; Campbell, Gabrielle; Degenhardt, Louisa; Nielsen, Suzanne; Ritter, Alison; Dale, Ola (2019-09-01). "Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine". Drugs. 79 (13): 1395–1418. doi:10.1007/s40265-019-01154-5. ISSN   1179-1950. PMC   6728289 . PMID   31352603.
  12. ↑ "Aptar Pharma Provides Unit-Dose Nasal Spray Technology for Opioid Overdose". Drug Development and Delivery. 2016-05-20. Retrieved 2019-11-18.
  13. 1 2 "Aptar gets FDA approval for Unidose nasal drug delivery device". NS Medical Devices. 2019-07-26. Retrieved 2020-07-09.
  14. 1 2 3 "Adapt Pharma's Nasal Spray Uses Unit-Dose Delivery System". Healthcare Packaging. 2016-05-19. Retrieved 2020-07-09.
  15. ↑ "State health agency welcomes Narcan donations". AdVantage. 2018-02-08. Retrieved 2020-07-09.
  16. ↑ Taylor, Phil (2016-09-13). "Aptar and BD join forces on auto-injector device". in-Pharma Technologist. Retrieved 2019-08-12.
  17. ↑ Rahman, Lu (2016-09-02). "Aptar Pharma teams up with BD to develop novel auto-injector". EPM Magazine. Retrieved 2019-08-12.
  18. ↑ Gormley, Brian (2016-02-25). "Propeller Health Joins With Aptar Pharma for Digitally Connected Medication Inhaler". Wall Street Journal. ISSN   0099-9660 . Retrieved 2019-08-12.
  19. ↑ Moukheiber, Zina. "With $20 Million In Funding, Propeller Health Partners With Aptar Pharma To Make Digital Medicines". Forbes. Retrieved 2019-08-12.
  20. ↑ Chaudhuri, Saabira (2020-07-10). "Soap Makers Are Cleaning Up Amid the Pandemic, but Can't Get Enough Hand Pumps". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-07-17.
  21. ↑ Taylor, Nick (2012-06-03). "Aptar to enter injectable device components with €165m buy". BioPharma Reporter. Retrieved 2019-08-12.
  22. ↑ McDougall, Andrew (2016-02-02). "AptarGroup acquires Mega Airless for €200 million". Cosmetics Design. Retrieved 2019-08-12.
  23. ↑ Johnson, Jim (2018-07-29). "AptarGroup buying CSP Technologies for $555 million". Plastics News. Retrieved 2019-08-12.
  24. ↑ "Aptar acquires Nanopharm and Gateway Analytical". www.oindpnews.com. Retrieved 2021-07-17.
  25. ↑ "Aptar acquires training device company Noble International". www.oindpnews.com. Retrieved 2021-07-28.
  26. ↑ cosmeticsdesign.com. "Aptar acquires makeup packaging company FusionPKG". cosmeticsdesign.com. Retrieved 2021-07-17.
  27. ↑ "US company Aptar signs binding agreement to buy FusionPKG". www.packaging-gateway.com. Retrieved 2021-07-17.
  28. ↑ "Cohero Health's digital respiratory assets get scooped up by AptarPharma". MobiHealthNews. 2020-11-05. Retrieved 2021-07-28.
  29. ↑ "Aptar acquires Cohero Health". www.oindpnews.com. Retrieved 2021-07-28.
  30. ↑ "Aptar Announces Exclusive Negotiations Regarding a Potential Acquisition of Voluntis to Expand in Digital Therapeutics". www.businesswire.com. 2021-06-22. Retrieved 2023-02-15.
  31. ↑ Norton, Leslie P. (2019-02-08). "The 100 Most Sustainable U.S. Companies". Barrons. Retrieved 2019-08-12.
  32. ↑ Norton, Leslie P. "These Are the 100 Most Sustainable Companies in America". www.barrons.com. Retrieved 2021-09-03.
  33. ↑ Norton, Leslie P. "Here Are the 100 Most Sustainable Companies Right Now". www.barrons.com. Retrieved 2021-09-03.
  34. ↑ "Aptar Named One of Barron's 100 Most Sustainable Companies in the U.S. for the Fourth Consecutive Year". Bloomberg.com. 2022-02-21. Retrieved 2022-06-27.
  35. ↑ "These 10 Companies Are Leading on Environmental Impact". JUST Capital. Retrieved 2021-08-29.
  36. ↑ Newsweek (2020-11-24). "America's Most Responsible Companies 2021". Newsweek. Retrieved 2021-08-27.
  37. ↑ Newsweek (2021-12-02). "America's Most Responsible Companies 2022". Newsweek. Retrieved 2022-06-27.
  38. ↑ Newsweek (2022-12-07). "America's Most Responsible Companies 2023". Newsweek. Retrieved 2023-01-19.
  39. ↑ "A List companies". www.cdp.net. Retrieved 2021-08-27.
  40. ↑ "Aptar Partners With TerraCycle's Loop Platform". Beauty Packaging. Retrieved 2021-08-05.
  41. ↑ "Green Growth 50 2021". Forbes. Retrieved 2023-01-19.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.